Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > Farma a question of you...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by princeofcuton Aug 28, 2015 10:33am
107 Views
Post# 24059193

Farma a question of you...

Farma a question of you...
.. assuming TST gets accepted (hopfully priority) my next objective is too handicap MCNA approval vs. other recently approved similars (one armed, small PIII, oncology (1st or 2nd line)), now there is a laundry list of recently approved drugs but any come to mind...TIA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities